Relapses in patients with giant-cell arteritis: prevalence, characteristics and associated clinical findings in a longitudinally followed cohort of 106 patients.

dc.contributor.author
Alba, Marco A.
dc.contributor.author
García Martínez, Ana
dc.contributor.author
Prieto González, Sergio
dc.contributor.author
Tavera Bahillo, Itziar
dc.contributor.author
Corbera Bellalta, Marc
dc.contributor.author
Planas Rigol, Ester
dc.contributor.author
Espígol Frigolé, Georgina
dc.contributor.author
Hernández Rodríguez, José
dc.contributor.author
Cid Xutglà, M. Cinta
dc.date.issued
2017-12-07T18:00:08Z
dc.date.issued
2017-12-07T18:00:08Z
dc.date.issued
2014-07
dc.date.issued
2017-12-07T18:00:08Z
dc.identifier
0025-7974
dc.identifier
https://hdl.handle.net/2445/118572
dc.identifier
651032
dc.identifier
25181312
dc.description.abstract
Giant cell arteritis (GCA) is a relapsing disease. However, the nature, chronology, therapeutic impact, and clinical consequences of relapses have been scarcely addressed. We conducted the present study to investigate the prevalence, timing, and characteristics of relapses in patients with GCA and to analyze whether a relapsing course is associated with disease-related complications, increased glucocorticoid (GC) doses, and GC-related adverse effects. The study cohort included 106 patients, longitudinally followed by the authors for 7.8 ± 3.3 years. Relapses were defined as reappearance of disease-related symptoms requiring treatment adjustment. Relapses were classified into 4 categories: polymyalgia rheumatica (PMR), cranial symptoms (including ischemic complications), systemic disease, or symptomatic large vessel involvement. Cumulated GC dose during the first year of treatment, time required to achieve a maintenance prednisone dose <10 mg/d (T10), <5 mg/d (T5), or complete prednisone discontinuation (T0), and GC-related side effects were recorded. Sixty-eight patients (64%) experienced at least 1 relapse, and 38 (36%) experienced 2 or more. First relapse consisted of PMR in 51%, cranial symptoms in 31%, and systemic complaints in 18%. Relapses appeared predominantly, but not exclusively, within the first 2 years of treatment, and only 1 patient developed visual loss. T10, T5, and T0 were significantly longer in patients with relapses than in patients without relapse (median, 40 vs 27 wk, p  < 0.0001; 163 vs 89.5 wk, p = 0.004; and 340 vs 190 wk, p = 0.001, respectively). Cumulated prednisone dose during the first year was significantly higher in relapsing patients (6.2 ± 1.7 g vs 5.4 ± 0.78 g, p = 0.015). Osteoporosis was more common in patients with relapses compared to those without (65% vs 32%, p = 0.001). In conclusion, the results of the present study provide evidence that a relapsing course is associated with higher and prolonged GC requirements and a higher frequency of osteoporosis in GCA.
dc.format
8 p.
dc.format
application/pdf
dc.language
eng
dc.publisher
Lippincott, Williams & Wilkins. Wolters Kluwer Health
dc.relation
Reproducció del document publicat a: https://doi.org/10.1097/MD.0000000000000033
dc.relation
Medicine, 2014, vol. 93, p. 194-201
dc.relation
https://doi.org/10.1097/MD.0000000000000033
dc.rights
cc-by (c) Alba, Marco A. et al., 2014
dc.rights
http://creativecommons.org/licenses/by/3.0/es
dc.rights
info:eu-repo/semantics/openAccess
dc.source
Articles publicats en revistes (Medicina)
dc.subject
Arteritis de cèl·lules gegants
dc.subject
Estadística mèdica
dc.subject
Giant cell arteritis
dc.subject
Medical statistics
dc.title
Relapses in patients with giant-cell arteritis: prevalence, characteristics and associated clinical findings in a longitudinally followed cohort of 106 patients.
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion


Ficheros en el ítem

FicherosTamañoFormatoVer

No hay ficheros asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)